PREVLAR: Phase 2a Randomized Trial to Assess the Safety and Efficacy of RRx-001 in the Attenuation of Oral Mucositis in Patients Receiving Head and Neck Chemoradiotherapy

Bonomi, Marcelo; Blakaj, Dukagjin; Kabarriti, Rafi; Colvett, Kyle; Takiar, Vinita; C. Biagioli, Matthew; Bar‐Ad, Voichita; Goyal, Sharad; C. Muzyka, Brian; J. Niermann, Kenneth; Abrouk, Nacer; Oronsky, Bryan; Reid, Tony; Caroen, Scott; T. Sonis, Stephen; J. Sher, David

doi:10.1016/j.ijrobp.2022.12.031

Public

PREVLAR: Phase 2a Randomized Trial to Assess the Safety and Efficacy of RRx-001 in the Attenuation of Oral Mucositis in Patients Receiving Head and Neck Chemoradiotherapy

Published in International Journal of Radiation Oncology*Biology*Physics • Jan 14, 2023

Authors:

Marcelo Bonomi

Dukagjin Blakaj

Rafi Kabarriti

Abstract

PURPOSE: No Food and Drug Administration-approved intervention exists for oral mucositis (OM) from chemoradiotherapy (CRT) used to treat head and neck cancers. RRx-001 is a hypoxia-activated, cysteine-directed molecule that affects key pathways involved in OM pathogenesis. This phase 2a, multi-insti...

Subject

Medicine

Mucositis

Head and neck cancer

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!